The relative effect of hypertension on stroke risk in women compared with men: random-effects meta-analysis



Downloads: 848
Hua Lee 1, Tong Sun, Mao Zhou, Yong Liu*
Author Affiliations
∗Correspondence author e-mail: Liu.8y@yahoo.com: China

 

 

Abstract

Stroke is a leading cause of mortality and morbidity worldwide, and hypertension is a major risk factor for both ischemic and hemorrhagic stroke. Although the relative effect of hypertension on stroke risk is similar in men and women, it is not established. Gender differences in the incidence and outcome of stroke have been reported, and growing evidence suggests possible differences in the relative effect of blood pressure on stroke risk. Data obtained from observational studies on the relative effect of hypertension on total, ischemic, and hemorrhagic stroke risk in women compared with men were used to conduct a random-effects meta-analysis. It was hypothesized that the relative effect of hypertension on stroke risk in women is smaller than in men. Random-effects meta-analysis resulted in a pooled relative risk for women compared with men of 1.4 (1.1, 1.8). Both fixed and random-effects meta-analyses for women and men without normal BP and with a definite hypertension effect resulted in respective pooled point estimates of 1.6 (1.3, 1.9) and 1.9 (1.5, 2.3). Both fixed and random-effects meta-analysis for women without prior myocardial infarction resultant from the study resulted in point estimates of 2.1 (1.7, 2.5) and 1.9 (1.5, 2.3), respectively. Similar statistics for men as well as both fixed and random-effects meta-analysis did not provide evidence of an increased stroke risk associated with elevated BP levels; respective pooled point estimates were 1.2 (0.7, 1.9), 1.1 (1.0, 1.3), and 1.0 (0.6, 1.5), respectively. All sensitivity analyses demonstrated the robustness of the estimates. Data presented in this investigation provide evidence for an increased risk of stroke in women compared with men.

Keywords: Stroke; Hypertension; Cohort study; Meta-analysis; female

Copyright © 2015 by The American Society for BioMedicine and BM-Publisher, Inc.

Article citationReferences
The citation data is computed by the following citation measuring services:

Google scholarcitedby

References

  1. Du XL, Simpson LM, Tandy BC, Bettencourt J, Davis BR. Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended. Int J Hypertens. 2001;2021:2261144.
  2. Yamal JM, Oparil S, Davis BR, et al.; ALLHAT Collaborative Research Group . Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. J Am Soc Hypertens. 2014;8(11):808-819.
  3. Piller LB, Simpson LM, Baraniuk S, et al.; ALLHAT Collaborative Research Group . Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014;29(11):1475-1483.
  4. Margolis KL, Davis BR, Baimbridge C, et al.; ALLHAT Collaborative Research Group . Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich). 2013;15(8):542-554.
  5. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;1:342–360.
  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA. 2002;288:2998–3007.
  7. Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK‐HARP‐I) study: biochemical efficacy and safety of simvastatin and safety of low‐dose aspirin in chronic kidney disease. Am J Kidney Dis. 2005;45:473–484.
  8. Margolis KL, Dunn K, Simpson LM, et al. Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non‐black patients randomized to pravastatin versus usual care: the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). Am Heart J. 2009;158:948–955.
  9. Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis.2008;52:412–424.
  10. Cholesterol Treatment Trialists' (CTT) Collaboration . Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 1995;75:1130–1134.
  11. Cholesterol Treatment Trialists' (CTT) Collaborators , Kearney PM, Blackwell L, et al. Efficacy of cholesterol‐lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta‐Lancet. 2008;371:117–125.
  12. LIPID Study Group (Long‐term Intervention with Pravastatin in Ischaemic Disease). Long‐term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow‐Lancet. 2002;359:1379–1387.
  13. Cholesterol Treatment Trialists' (CTT) Collaboration . Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Am J Cardiol. 1995;75:1130–1134.
  14. Cholesterol Treatment Trialists' (CTT) Collaborators , Kearney PM, Blackwell L, et al. Efficacy of cholesterol‐lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta‐Lancet. 2008;371:117–125.
  15. Holdaas H, Fellstrom B, Cole E, et al. Long‐term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant.2005;5:2929–2936.
  16. Ford I, Murray H, Packard CJ, et al. Long‐term follow‐up of the West of Scotland Coronary Prevention Study. N Engl J Med.2007;357:1477–1486.
  17. Brouwers FP, Asselbergs FW, Hillege HL, et al. Long‐term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:ten years of follow‐up of Prevention of Renal and Vascular End‐stage Disease Intervention Trial (PREVEND IT). Am Heart J.2011;161:1171–1178.
  18. Maitland‐van der ZA, Lynch A, Boerwinkle E, et Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG‐CoA reductase inhibitors in preventing cardiovascular disease in high‐risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics. 2008;18:651–656.
  19. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev.2009;2:CD007784.

Research Article


DOI: http://dx.doi.org/10.18081/2333-5106/015-3/482-494
American Journal of BioMedicine 2015, Volume 3, Issue 3, pages 154-175
Received February 19, 2015; accepted July; 17, 2015, Published August 16, 2015

How to cite this article
Lee H, Sun T, Zhou M, Liu Y. The relative effect of hypertension on stroke risk in women compared with men: random-effects meta-analysis. American Journal of BioMedicine 2015;3(3):154-175
Research Article
1. Abstract
2. Keywords
3. Introduction
5. Results
6. Discussion
7. References

Article metric